The impact of type 2 diabetes mellitus on cancer-specific survival A Follow-Up Study in Sweden
The impact of type 2 diabetes mellitus on cancer-specific survival A Follow-Up Study in Sweden
复制标题
DOI：
10.1002/cncr.26420
复制
发表时间：
2012-03-01
期刊：
影响因子：
6.2
通讯作者：
Hemminki, Kari
中科院分区：
文献类型：
--
作者：
Liu, Xiangdong;Ji, Jianguang;Hemminki, Kari
背景：早期研究表明 2 型糖尿病 (T2DM) 会改变罹患多种癌症的风险，但人们对 T2DM 对癌症预后的影响知之甚少。本报告的作者以瑞典全国人口登记为基础，比较了患有和不患有 T2DM 的癌症患者的病因特异性生存率。方法：从全国瑞典医院出院登记处确定 T2DM 患者，并从瑞典癌症登记处记录癌症情况。使用 Cox 回归模型计算风险比 (HR)，以比较患有和不患有 T2DM 的癌症患者之间特定原因生存率的变化。结果：在 1016,105 名癌症患者中，16,123 名在诊断癌症之前曾因 T2DM 住院。患有 T2DM 的癌症患者的死亡率显着高于非 T2DM 的癌症患者（原因特异性 HR，1.38；95% 置信区间，1.35-1.41）。除了乳腺癌和前列腺癌的肿瘤和转移分类外，患有或不患有 T2DM 的癌症患者的主要癌症的 TNM 分期分布没有差异。结论：目前的结果表明，与患有非 T2DM 癌症的患者相比，随后诊断出患有癌症的 T2DM 患者的特定原因死亡率风险更高。癌症2012； 118：1353-61。 (C) 2011 年美国癌症协会。
BACKGROUND: Earlier studies have suggested that type 2 diabetes mellitus (T2DM) alters the risk of developing a variety of cancers, but little has been known about the impact of T2DM on cancer prognosis. On the basis of nationwide population-based Swedish registries, the authors of this report compared the cause-specific survival among cancer patients with and without T2DM. METHODS: Patients with T2DM were identified from the nationwide Swedish Hospital Discharge Register, and cancers were recorded from the Swedish Cancer Registry. Hazard ratios (HRs) were calculated using Cox regression models to compare variations in cause-specific survival between cancer patients with and without T2DM. RESULTS: Of the 1016,105 cancer patients, 16,123 had been hospitalized with T2DM before their diagnosis of cancer. The mortality rate was significantly higher among cancer patients with T2DM than among those without T2DM (cause-specific HR, 1.38; 95% confidence interval, 1.35-1.41). There were no differences in TNM stage distribution among cancer patients with or without T2DM for the main cancers, with an exception of tumor and metastatic classifications for breast cancer and prostate cancer, respectively. CONCLUSIONS: The current results indicated that patients with T2DM who are diagnosed with a subsequent cancer are at an increased risk for cause-specific mortality compared with patients who have cancer without T2DM. Cancer 2012; 118: 1353-61. (C) 2011 American Cancer Society.